<![CDATA[Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=31687>Sun, 05 Apr 2026 01:10:02 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma]]>https://www.newswire.co.kr/newsRead.php?no=876440Tue, 02 Oct 2018 20:00:00 +0900<![CDATA[시애틀 제네틱스와 다케다제약, CD30발현 말초 T세포 림프종에 ‘애드세트리스’를 1차 치료제로 사용하여 평가한 긍정적 3상 ECHELON-2임상시험 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=876441Tue, 02 Oct 2018 20:00:00 +0900